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Abstract
Background: Chronic rejection is the single biggest cause of premature kidney graft failure. HLA antibodies (Ab)
are an established prognostic biomarker for premature graft failure so there is a need to test whether treatment
decisions based on the presence of the biomarker can alter prognosis. The Optimised TacrolimuS and MMF for HLA
Antibodies after Renal Transplantation (OuTSMART) trial combines two elements. Firstly, testing whether a routine
screening programme for HLA Ab in all kidney transplant recipients is useful by comparing blinding versus
unblinding of HLA Ab status. Secondly, for those found to be HLA Ab+, testing whether the introduction of a
standard optimisation treatment protocol can reduce graft failure rates.
Methods: OuTSMART is a prospective, open-labelled, randomised biomarker-based strategy (hybrid) trial, with two
arms stratified by biomarker (HLA Ab) status. The primary outcome was amended from graft failure rates at 3 years
to time to graft failure to increase power and require fewer participants to be recruited. Length of follow-up
subsequently is variable, with all participants followed up for at least 43 months up to a maximum of 89 months.
The primary outcome will be analysed using Cox regression adjusting for stratification factors. Analyses will be
according to the intention-to-treat using all participants as randomised. Outcomes will be analysed comparing
standard care versus biomarker-led care groups within the HLA Ab+ participants (including those who become HLA
Ab+ through re-screening) as well as between HLA-Ab-unblinded and HLA-Ab-blinded groups using all participants.
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Discussion: Changes to the primary outcome permit recruitment of fewer participants to achieve the same
statistical power. Pre-stating the statistical analysis plan guards against changes to the analysis methods at the point
of analysis that might otherwise introduce bias through knowledge of the data. Any deviations from the analysis
plan will be justified in the final report.
Trial registration: ISRCTN registry, ID: ISRCTN46157828. Registered on 26 March 2013;
EudraCT 2012–004308-36. Registered on 10 December 2012.
Keywords: Human leucocyte antigen antibodies, Renal transplantation, Randomised controlled trial, Graft failure,
Immunosuppression, Time-to-event, Statistical analysis plan
Update
This update relates to the OuTSMART trial protocol, a
randomised controlled trial testing whether a combined,
structured, biomarker-screening programme and opti-
mised immunosuppression treatment regimen can re-
duce risk of graft failure in kidney transplant patients.
This update should be read in conjunction with the
original protocol publication [1].
Summary of design
OuTSMART is a prospective, open-labelled, randomised,
biomarker-based strategy (hybrid) trial design, with two
arms stratified by biomarker (human leucocyte antigen
(HLA) antibody (Ab)) status. Recruitment will take place
in 12 renal transplant units, recruiting for 45months with
recruits followed up intensively for at least 32months
(maximum 64months) and primary endpoint assessed by
remote evaluation after 43months post randomisation is
achieved by all.
Recipients of cross-match-negative transplants aged
18–75 years, and longer than 1 year post transplant with
an estimated glomerular filtration rate (eGFR) ≥ 30 will
be recruited into the trial.
The first stratification will result from blood-test
screening for HLA Ab. Approximately 35% will be HLA
positive (Ab+), with ~ 65% HLA negative (Ab−). The
HLA Ab+ patients will be further screened with single
antigen beads to determine whether donor-specific anti-
bodies (DSA) are present (~ 1/6 DSA and 5/6 non-
DSA). Thus, biomarker stratification leads to three
groups (DSA+, non-DSA+ and HLA Ab−).
The second stratification will be based on current im-
munosuppression to ensure balanced numbers already
on tacrolimus (Tac) or mycophenolate mofetil (MMF) in
each group. The final stratification will be by site.
HLA Ab+ patients will be randomised 1:1 into either
blinded standard care (SC) or unblinded biomarker led-
care (BLC). Patients in the former (groups A1 and A2 in
the flow chart in Fig. 1) will be blind to their biomarker
status and will remain on baseline immunotherapy,
whereas patients in the latter (groups B1 and B2 in Fig.
1) will know their HLA Ab status and will be offered
‘treatment’.
HLA Ab− patients will remain on their existing im-
munotherapy and randomised 1:1 into either the blinded
(group C) or the unblinded group (D), with only the lat-
ter knowing their HLA Ab status. Both these groups will
receive regular Ab-status monitoring for the first 32
months. Those patients who become positive during
subsequent screening rounds (~ 10% per year) will be
moved to the appropriate HLA Ab+ groups (DSA+ or
non-DSA+) for final data analysis (see Fig. 1).
All patients in group D found to be positive on second
or subsequent rounds will be offered the same ‘treat-
ment’ as those patients who were positive in the first
screening round and be intensively followed up for an
additional 32 months from the time that they become
positive. Thus, the maximum amount of time that any
single patient may remain in intensive follow-up is 64
months. New patients will be recruited to the study at
each successive screening round.
The primary endpoint is time to graft failure in HLA
Ab+ patients, where graft failure is defined as re-starting
dialysis or requiring a new transplant.
Change in primary outcome and sample size
The proportions of patients presenting with HLA Ab+
antibodies were closely monitored throughout recruit-
ment to check that the assumptions and the sample size
calculations were valid.
Sixteen months into recruitment (February 2015),
prevalence (at randomisation) and incidence (through
re-screening) rates of HLA Ab+ DSA were lower than
originally expected. Nine percent prevalence and 3% in-
cidence rates were expected [1] but 5.8% and 1.6% were
observed, respectively. Consequently, it was estimated
that approximately 4000 participants were needed to
achieve the 278 HLA Ab+ DSA participants required for
80% power for the superiority hypothesis in HLA Ab+
DSA participants. This far exceeded our original
estimated sample size of 2522 participants.
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Therefore, we decided to change the primary outcome
from graft failure rate at 3 years’ follow-up to time to
graft failure. This allowed a reduction in the required
sample size to 165 participants in the DSA group from
an estimated 2357 participants overall. This reduction is
achieved from the increased statistical power using time
to graft failure which utilises more information from
each observation [2].
These changes were approved by the OuTSMART
Data Monitoring Committee (DMC), OuTSMART Trial
Steering Committee (TSC), the London-Hampstead
Research Ethics Committee (REC) and the Medicines
and Healthcare products Regulatory Agency (MHRA).
New sample size calculation
The updated sample size calculation was based on using
time to graft failure as the primary endpoint and DSA
prevalence and incidence rates observed from 16months
of recruitment. Other parameters were as per the ori-
ginal sample size calculation. The sample size calculation
was carried out in Cytel’s East software v6.3 [3]
As previously, hypothesis testing will be sequential [1].
Superiority will be tested first in the HLA Ab+ groups to
demonstrate the efficacy of the treatment. If this analysis
is significant, then non-inferiority will be tested for the
entire population to demonstrate the clinical utility of
the biomarker screening. We calculated the sample size
needed to show the superiority of the treatment opti-
misation for biomarker-positive patients using the hy-
potheses as follows:
Hypothesis 1.1: HLA Ab+ patients with DSA,
randomised to standard care (A1) will show higher
graft failure rates than patients randomised to
biomarker-led care (B1).
We hypothesise that the experimental treatment will
bring the failure rate of group B1 down to that of
non-DSA patients in SC (A2). Assuming that a 30%
failure rate for group A1 (as in [4]), and a 16% failure
rate for group B1 at 3 years’ follow-up corresponds to
a hazard ratio (HR) of 0.489, the expectation is for
Fig. 1 OuTSMART flow diagram. *Randomisation performed on results of a recruit’s first screening test. Those with human leucocyte antigen (HLA)
antibodies (Ab) undergo no further screening as part of the trial (but serum will be stored for analysis of HLA Ab profiles later). †Those initially HLA Ab−
undergo routine screening every 8months. There is no second randomisation: if a recruit allocated to blinded standard care (group C) becomes HLA
Ab+ (black lines), they remain in the standard care group (group A1 or A2). If in unblinded standard care group (D), they change to unblinded
biomarker-led treatment care (group B1 or B2) (orange lines). €Numbers in each group are those anticipated at the end of study
Stringer et al. Trials          (2019) 20:476 Page 3 of 9
11% and 21% chronic rejection (CR) rates among pa-
tients with DSA in group A1 at 1 and 2 years’ follow-
up, respectively (as in [4]). Extrapolating, based on a
HR of 0.489, we expect BLC to reduce those CR rates
to 5.5% and 10.89% at 1 and 2 years, respectively.
After 3 years’ follow-up, we assume a linear increase
in the failure rate in group A1 per year (using the
difference between the year-2 and year-3 failure rates;
a 9% increase in the failure rate per year) with the
same HR of 0.489.
Using a variable follow-up design, assuming an average
accrual monthly rate of 3.6 patients per month and a
minimum follow-up time of 43 months (with accrual
period of 46 months for a maximum follow-up of 89
months), recruiting 165 patients with DSA would allow
us to observe 23/83 (28%) events of CR in patients
under BLC (B1), and 39/82 (47%) in the SC group (A1).
This would provide 80% power and 5% type I error, for a
two-sided log-rank test.
Hypothesis 1.2: HLA Ab+ patients, with non-DSA,
randomised to standard care (A2) will show higher
graft failure rates than patients randomised to
biomarker-led care (B2).
We hypothesise that the experimental treatment will
bring the failure rate of group B2 down to that of bio-
marker-negative patients in SC (C). Assuming a 16%
failure rate for group A2 (as in [4]), and a 6% failure
rate for group B2 at 3 years’ follow-up corresponds to a
HR of 0.351. Based on Lachman et al. [4] the expect-
ation is for 3% and 11% of CR among patients with
non-DSA in SC at 1 and 2 years’ follow-up, respectively.
Extrapolating based on a HR of 0.351, we expect BLC
to reduce CR to 1.1% and 4.1% at 1 and 2 years, re-
spectively. After 3 years’ follow-up, we assume a linear
increase in the failure rate in group A2 per year (using
the difference between the year-2 and year-3 failure
rate; a 5% increase in the failure rate per year) with the
same HR of 0.351.
Using a variable follow-up design (patients followed
until failure, drop out or end of minimum follow-up),
assuming an average accrual monthly rate of 15.5 pa-
tients per month, and a minimum follow-up time of
22.4 months, recruiting 296 patients with non-DSA,
would allow us to observe 8/149 (5.3%) events of CR in
patients under BLC, and 21/147 (14%) in the SC group
(total duration = 41.5 months). This would provide 80%
power to determine a statistically significant difference
between SC and BLC, using a log-rank test, with a two-
sided type-I error rate.
The numbers enrolled in groups A and B include
those patients initially enrolled in groups C or D who
become HLA Ab+ during re-screening.
Hypothesis 2: All patients randomised to unblinded
screening (combined groups B1 + B2 + D) will show
equal or lower graft failure rates than all patients
randomised to blinded screening (combined groups
A1 + A2 + C), irrespective of biomarker status.
We calculated the sample size needed to show the non-
inferiority of all unblinded patients compared to all
blinded patients as follows:
At the end of the trial, we expect 58% of patients to be
in the HLA Ab− groups, 7% DSA+ groups and 35% non-
DSA+ groups (after drop outs). At the time of planning
the OuTSMART study, we calculated that, based on
these assumptions, all patients randomised to SC com-
bined would experience 13.9% of CR. We established a
non-inferiority limit of 5% absolute difference in rate of
CR at 3 years, so that the BLC group would be consid-
ered inferior to SC with a CR rate of 18.9% or higher
(expectation under the null hypothesis). This corre-
sponds to a HR of 1.4 under the null hypothesis, and a
HR of 0.63 under the alternative.
Recruiting 672 patients over a period of 13.2 months,
at an average accrual rate of 51 patients per month, and
a minimum follow-up of 18.21 months, would allow us
to observe 22/337 (6.5%) events of CR in the SC group,
and 32/335 (9.5%) in the BLC group. This would provide
90% power to demonstrate non-inferiority with a one-
sided 95% confidence interval (CI) of the HR estimated
using a Cox regression model. Given the above propor-
tions, this requires enrolling 336 patients in each of
groups C and D and this should allow 423 total HLA
Ab− patients to reach the primary endpoint.
Overall sample size
It was estimated that a total of 2357 participants were
required to achieve the 165 HLA Ab+ DSA participants
needed (using observed DSA incidence and prevalence
rates). Because of this requirement to recruit sufficient
DSA participants, the recruits to the other groups are
likely to be more than the minimum required for statis-
tical power for the individual hypotheses.
HLA Ab+ DSA rates continued to be monitored
following these changes and observed rates increased.
Recruitment was stopped once 165 HLA Ab+ DSA par-
ticipants were reached (through randomisation or re-
screening); 2037 participants were randomised in total.
Re-screening continued until 8 months after the end of
recruitment so that all participants were re-screened at
least once.
Change in follow-up
In the original protocol, participants were to be followed
up every 4 months. This was reduced to 8-monthly visits
to free up staffing resources for recruitment. Therefore,
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all data that was to be recorded every 4months from
randomisation will instead be recorded every 8months.
Each patient’s lipid profile will be measured every 16
months instead of every 12months.
Length of follow-up was amended to be variable such
that each participant will undergo 32months of inten-
sive follow-up post randomisation (or additionally 32
months after becoming HLA Ab+ at one of the re-
screening rounds). Participants will be followed up with
8-monthly clinic visits in the intensive follow-up period.
Subsequently, participants will be followed up remotely
(with no additional contact other than routine care) until
the last randomised participant reaches 43 months post
randomisation As the accrual period is 46 months, par-
ticipants will, therefore, be followed up for a maximum
of 89months.
In the 3 months prior to the conclusion of the study
(the last randomised participant reaching 43months
post randomisation) all participants’ hospital records will
be checked (other than participants already recorded as
having graft failure, having died or having chosen to
withdraw from data collection) for graft failure or death
in the preceding follow-up period, with dates recorded if
these events have occurred. If a participant does not
have a routine clinic visit booked for this time period,
the research staff at site will contact the participant by
phone to determine whether graft failure has occurred.
This assessment for each participant will only occur
once in the given 3-month time period, at which point
the participants’ involvement in the study will be
completed.
Change in secondary outcomes
With these changes, the list of secondary clinical end-
points has been amended to the following:
 Time to graft failure in patients randomised to
blinded HLA Ab screening versus those randomised
to unblinded screening. Graft failure will be defined
as re-starting dialysis or requiring a new transplant
 Patient survival
 Graft dysfunction, as assessed by two separate
measures, presence of proteinuria (protein/
creatinine ratio (PCR) > 50 or albumin/creatinine
ratio (ACR) > 35) and change in eGFRs over 32
months
 Rates of biopsy-proven rejection
 Rates of culture- or polymerase-chain-reaction-
positive infection, biopsy-proven malignancy and
diabetes mellitus
 Health economic analysis of outcomes
 Analysis of adherence and perceptions of risk for the
BLC group
The definition of graft dysfunction as a secondary
outcome has been amended. Originally, this was a com-
posite of two binary endpoints defined as either the
presence of proteinuria or a negative change in eGFR.
Negative change in eGFR was a binary indicator defined
as having a negative slope from a linear regression ana-
lysis of the serial eGFRs from baseline to 32 months and
having to yield an adjusted R2 value of ≥ 0.35 and a p
value of ≤ 0.05 [5]. Consequent to the reduction in num-
ber of study visits, there is a reduction in the number of
eGFR measurements between baseline and 32months.
The reduction in the number of measurements would
considerably reduce the probability of the linear regres-
sion being valid based on the criteria stated where there
was a negative slope. This reduces the power to detect a
difference (if one exists) between groups as there will be
fewer events. A more powerful approach is to use a
continuous measure of Modification of Diet in Renal
Disease (MDRD) eGFR.
Proteinuria was defined as a PCR of > 50 from a urine
sample. This definition has also changed as some sites
use the ACR instead of the PCR.
Graft dysfunction will, therefore, be assessed by two
separate measures, presence of proteinuria (PCR > 50 or
ACR > 35) at 32 months and change in eGFRs over 32
months. eGFRs will be calculated using the MDRD.
Mean eGFR slopes at 32 months will be compared be-
tween arms, using all available observations between
baseline and 32months in a linear mixed model.
Rates of acute rejection will still be assessed as stated
in the original protocol except that rates will be assessed
at the 32months’ follow-up visit instead of at 3 years
(36 months). There was no change to any of the other
clinical outcomes.
The secondary scientific endpoints (change in HLA
Ab characteristics, laboratory parameters of T- and B-
cell phenotypes and responsiveness, numbers and
phenotype of circulating CD34+) have been removed as
formal secondary endpoints due to lack of resources.
Change in inclusion/exclusion criteria
The inclusion criteria were amended to increase the age
range from 18 to 70 to 18 to 75 years, on the realisation
that many patients over 70 years of age are fit and
healthy and thus could be considered for inclusion in
the trial. ‘History of an ongoing or previous infection
(no time limit) that would prevent optimisation of
immunosuppression, including ocular Herpes simplex’
was removed as an exclusion criterion, after feedback
that the vague nature of the criterion (for example, in
not defining which infections were important) was being
interpreted differently within and across sites and was,
therefore, impacting on recruitment rates. As the opti-
misation for each participant was tailored to that
Stringer et al. Trials          (2019) 20:476 Page 5 of 9
individual, previous infections could be accommodated
without excluding them. This was expected to standard-
ise the selection of participants across all sites and in-
crease recruitment rates.
Statistical analysis plan
The statistical analysis plan has been revised in light of
these changes and is outlined below.
All analyses will use the intention-to-treat population
(all randomised participants included and according to
allocated arm) unless otherwise stated.
Those patients who become positive during subse-
quent screening rounds will be moved to the appro-
priate HLA Ab+ groups (DSA+ or non-DSA+) for
analysis. These participants will be included from the
time that they became HLA Ab+ (date sample for
screening was taken). For the analysis using all partic-
ipants, these participants will be included from the
time of randomisation.
This statistical analysis plan does not cover the health
economic and health belief (adherence and perception of
risk) outcomes which will not be reported in the primary
paper but will instead be reported in separate papers.
Data description
A Consolidated Standards of Reporting Trials (CON-
SORT) flow chart will be constructed (Fig. 2). This will
include the number of eligible patients, number of
patients agreeing to enter the trial, number of patients
refusing; number of HLA Ab+ and Ab− patients, overall
and by treatment arm: the number continuing through
the trial, the number lost to follow-up or withdrawn,
and the numbers excluded/analysed.
Baseline descriptions of participants will be tabulated
by trial arm within HLA status and overall. Means and
standard deviations (medians and inter-quartile ranges
(IQR) if skewed) or numbers and proportions will be
presented as appropriate. Especially relevant factors that
will be tabulated are age, sex, HLA mismatches, baseline
eGFR, site, previous treatment and time from transplant-
ation. No significance testing will be used to test baseline
differences between arms.
Frequencies and descriptive statistics of all primary
and secondary outcome measures will be reported. Im-
munosuppressive drugs and doses prescribed to each
group of patients will be summarised.
All descriptives will be broken down by HLA status.
Where appropriate, descriptives for HLA Ab+ partici-
pants may be further broken down by whether they were
HLA Ab+ at randomisation or through re-screening.
Those who became HLA Ab+ at re-screening may also
be described separately prior to becoming HLA Ab+
and after becoming HLA Ab+.
Primary analysis
Superiority
H0: hA1(t) = hB1(t) and hA2(t) = hB2(t)
H1: hA1(t) ≠ hB1(t) and hA2(t) ≠ hB2(t)
To test superiority for the primary outcome in the bio-
marker (HLA Ab)-positive groups (hypotheses 1.1 and
1.2), we will use the Cox proportional hazards models to
estimate the graft failure HR between the BLC and SC
groups and test at the 5% level of significance. Results
will be given as estimates and 95% CIs.
Within the model, we will adjust for previous im-
munosuppression regimen and research site (as these
are the randomisation stratification factors) for increased
statistical efficiency. We will check the proportional haz-
ards assumption by examining Kaplan-Meier plots and
by testing for an interaction between group (BLC or SC)
and time to graft failure within the models.
Non-inferiority
H0: hUnblind(t)/hBlind(t) ≥ δ
H1: hUnblind(t)/hBlind(t) < δ
To test for non-inferiority of the unblinded groups
compared to the blinded groups (hypothesis 2.1), we will
use a Cox proportional hazards model to estimate the
graft failure HR. We will adjust for the stratification
factors in the model as outlined above and check the
proportional hazards assumption by examining Kaplan-
Meier plots and by testing for an interaction between
group (unblinded/blinded) and time to graft failure. We
will conclude non-inferiority if H0 gets rejected at 5%
significance, and the corresponding upper bound of the
95% CI for the HR excludes the limit δ (HR of 1.4).
Secondary analyses
We will use a similar procedure using Cox regression
for the analysis of secondary time-to-event (survival)
outcomes. Where numbers allow, secondary binary out-
comes will be analysed using logistic regression with
adjustment for stratification factors. Where numbers are
too small for this, a Z-test or Fisher’s exact test will be
used. For continuous secondary outcomes, linear regres-
sion will be used (or linear mixed models where ac-
counting for repeated measures), adjusting for baseline
values of the outcome and stratification factors. Trans-
formations will be considered where data is skew.
Results will be given as estimates (odds ratios or differ-
ences in proportions) and 95% CIs.
No formal adjustment of p values for multiple test-
ing is necessary. However, care will be given to the
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interpretation of inference for the numerous second-
ary outcomes.
Harms
Adverse events (AE), adverse reactions (AR), serious ad-
verse events (SAE) and serious adverse reactions (SAR)
will be summarised by group (within trial arm and HLA
status) as proportions and 95% CIs, broken down by
body system code where there are sufficient numbers.
Missingness
Missing baseline data should not be an issue for the
primary analysis. Some of the secondary or exploratory
analyses may use other baseline variables; if these contain
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) diagram for OuTSMART. Ab antibody, HLA human leucocyte antigen, DSA
donor-specific antibodies
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missing data, the number with complete data will be re-
ported and they will be imputed using a method suitable
to the variable as per the recommendations of White and
Thompson [6].
For missing outcome data, if post-treatment variables,
such as compliance with treatment, are found to be predict-
ive of drop out, multiple imputation will be considered.
Per-protocol analyses
An exploratory per-protocol analysis will be carried out
comparing time to graft failure in only those participants
who were optimised to the full treatment protocol (as
defined in [1]) in the unblinded arm against all blinded
participants, within both the HLA Ab+ DSA and HLA
Ab+ non-DSA groups.
In addition, if there are concerns about compliance,
complier average causal effect (CACE) analysis [7] will
be considered as a less biased way of estimating treat-
ment efficacy.
Exploratory/subgroup analyses
The trial protocol states that where, because of insuffi-
cient data on donor mismatches, for instance, the
laboratory has difficulty labelling an HLA Ab as either a
DSA or non-DSA, the Ab will be regarded as a non-
DSA. Therefore, it is likely that the non-DSA group will
contain patients with actual DSA. Therefore, an explora-
tory subgroup analysis will be carried out within the
HLA Ab+ non-DSA group using only those participants
within this group that have definite non-DSA.
Exploratory analyses will clearly be stated as such in
any output and will be interpreted accordingly.
There are no other planned subgroup analyses.
Interim analyses
There are no planned interim analyses.
Software
Data management: an online data collection system for
clinical trials (MACRO; Elsevier) will be used. This is
hosted on a dedicated server at King’s College London
(KCL) and managed by the Kings Clinical Trials Unit
(KCTU).
Statistical analysis: Stata version 15.1 [8] and/or R [9]
will be used for all statistical analyses.
Discussion
This manuscript was written based on OuTSMART
protocol version 13 and Statistical Analysis Plan version
2.2. This statistical analysis plan publication will help to
avoid bias; pre-stating that the analysis plan helps to pre-
vent changes to the analysis methods arising from know-
ledge of the data that may introduce bias. If there are
any deviations from this statistical analysis plan, these
will be outlined and justified in the final report.
Trial status
OuTSMART has now completed recruitment and partic-
ipants are in follow-up until June 2020. All HLA re-
screening has also been completed. Two thousand and
thirty-seven participants were randomised, of which 198
are HLA Ab+ with DSA following re-screening.
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